Bionure is a clinical stage biotechnology company, an academic spin-off from IDIBAPS – Hospital Clinic of the University of Barcelona and the Spanish National Council CSIC (Spain). The company was founded in 2009 and has its headquarters in Barcelona, Spain.
Based on more than 15-year of research in neuroprotection, the company develops new first-in-class disease-modifier drugs able to slow down, stop or reverse the damaging process affecting neurons for the treatment of degenerative, ischemic, toxic and inflammatory diseases of the nervous system.
Since there are very high unmet needs associated to these diseases, Bionure aims at becoming a therapeutic game changer and bringing significant benefit to thousands to millions of patients enduring serious disabilities.
Bionure’s lead program demonstrated neuroprotective activity in several preclinical models and has successfully completed a clinical phase 1 study in the UK. In 2020, the company plans to start a phase 2 proof-of-concept trial in optic neuritis (orphan drug designation) and multiple sclerosis, to prove the efficacy of the compound in patients affected by neuronal damage.
Bionure has built a seasoned team of pharma R&D and corporate development professionals and an efficient ecosystem of vendors, CROs and advisors, including prominent scientific and clinical experts in the field of neurodegeneration, to further support the development of its programs.
The company is privately-held. Initially supported by business angels, family offices and public grants, the company started to diversify its investor base with a first institutional VC, Alta Life Sciences, which led in 2018 the Series A financing round to support the Phase 1 program of BN201 and will help anchoring syndication of investors at futures rounds.
Top-tier professionals and experts working towards a common goal
Drug discovery interest for remyelinating drugs has recently increased. However, remyelination can be futile if axons are not preserved (neuroprotection)
We look forward to pursuing partnership opportunities with industry leaders.
Bionure has participated in the following projects. These projects have received funding from the Ministry of Science and Innovation, within the National Plan for Scientific Research, Development and Technological Innovation 2008-2011. They have been co-financed by the European Regional Development Fund (ERDF).
Bionure has received non-dilutive funding support from the following local, national and european governments:
Nuevas aproximaciones terapéuticas para la Esclerosis Múltiple y la Esclerosis Lateral Amiotrófica: efectos modificadores de la enfermedad y neuroprotección
(expediente IPT-010000-2010-035) liderado por Advanced in Vitro Cell Technologies SA y en el que también participan Neurotec Pharma SL y el Consorci Institut d’Investigacions Biomèdiques August Pi i Sunyer.
STOP-ELA: Aproximación multi-tecnológica para el desarrollo de nuevas terapias y sistemas avanzados de administración farmacológica para la Esclerosis Lateral Amiotrófica
(expediente IPT-2011-1091-900000) liderado por Neurotec Pharma SL y en el que también participan Advanced in Vitro Cell Technologies SA, Palo Biofarma SL, Natac Biotech SL, Universidad de Zaragoza y el Consorci Institut d’Investigacions Biomèdiques August Pi i Sunyer
Desarrollo de terapias neuroprotectoras para Esclerosis Múltiple
(expediente IPT-2011-1312-900000) liderado por Digna Biotech SL, y en que también participan la Fundación Privada Institut d’Investigació Biomèdica de Bellvitge y el Consorci Institut d’Investigacions Biomèdiques August Pi i Sunyer.